The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) last traded at $40.60, down -12.99% from the previous session.
Data from the available sources indicates that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is covered by 19 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $143.00 and a low of $49.00, we find $96.00. Given the previous closing price of $46.66, this indicates a potential upside of 105.74 percent. RARE stock price is now 1.33% away from the 50-day moving average and -20.85% away from the 200-day moving average. The market capitalization of the company currently stands at $2.88B.
In total, 3 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $93.37 as their price target over the next twelve months.
On November 03, 2022, Robert W. Baird Upgraded its previous ‘Neutral’ rating to ‘Outperform’ on the stock keeping its target price maintained at $50, while ‘Guggenheim’ rates the stock as ‘Buy’.
In other news, KAKKIS EMIL D, President & CEO sold 19,582 shares of the company’s stock on Dec 30. The stock was sold for $892,352 at an average price of $45.57. Upon completion of the transaction, the President & CEO now directly owns 541,108 shares in the company, valued at $21.97 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 21, SVP, Chief Accounting Officer Huizenga Theodore Alan sold 2,031 shares of the business’s stock. A total of $89,283 was realized by selling the stock at an average price of $43.96. This leaves the insider owning 16,197 shares of the company worth $0.66 million. Insiders disposed of 55,103 shares of company stock worth roughly $2.24 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RARE stock. A new stake in Ultragenyx Pharmaceutical Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $105,862,000. EVENTIDE ASSET MANAGEMENT, LLC invested $12,415,000 in shares of RARE during the first quarter. In the first quarter, JACOBS LEVY EQUITY MANAGEMENT, INC acquired a new stake in Ultragenyx Pharmaceutical Inc. valued at approximately $8,968,000. ALLY BRIDGE GROUP (NY) LLC acquired a new stake in RARE for approximately $8,813,000. SPHERA FUNDS MANAGEMENT LTD. purchased a new stake in RARE valued at around $7,052,000 in the second quarter. In total, there are 333 active investors with 97.80% ownership of the company’s stock.
With an opening price of $46.50 on Monday morning, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) set off the trading day. During the past 12 months, Ultragenyx Pharmaceutical Inc. has had a low of $33.36 and a high of $85.53. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.50, and a quick ratio of 4.40. The fifty day moving average price for RARE is $40.07 and a two-hundred day moving average price translates $51.30 for the stock.
The latest earnings results from Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$2.26, missing analysts’ expectations of -$1.75 by -0.51. This compares to -$1.08 EPS in the same period last year. The company reported revenue of $90.7 million for the quarter, compared to $81.65 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.09 percent. For the current quarter, analysts expect RARE to generate $96.2M in revenue.
Ultragenyx Pharmaceutical Inc.(RARE) Company Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.